Lerch, Erika

Up a level
Export as [feed] RSS
Group by: Item Type | No Grouping
Number of items: 7.

Journal Article

Zander, Thilo; Pabst, Thomas; Schär, Sämi; Aebi, Stefan; Mey, Ulrich; Novak, Urban; Lerch, Erika; Rhyner Agocs, Gaëlle; Goede, Jeroen; Maniecka, Zuzanna; Hayoz, Stefanie; Rüfer, Axel; Renner, Christoph; Driessen, Christoph (2023). Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial. Leukemia, 37(3), pp. 699-701. Springer Nature 10.1038/s41375-023-01809-z

Zander, Thilo; Pabst, Thomas; Schär, Sämi; Aebi, Stefan; Pabst, Tobias; Mey, Ulrich; Novak, Urban; Lerch, Erika; Rhyner, Gaëlle; Goede, Jeroen; Maniecka, Zuzanna; Hayoz, Stefanie; Rufer, Axel; Renner, Christoph; Driessen, Christoph (2021). P-227: Alternate day dosing of pomalidomide in patients with refractory/relapsed multiple myeloma (RRMM): Results of a multicenter, single arm phase 2 trial (SAKK 39/16 OptiPOM Study). Clinical lymphoma, myeloma and leukemia, 21(Suppl. 2), S165-S165. Elsevier 10.1016/S2152-2650(21)02354-5

Ghilardi, Guido; Pabst Müller, Thomas Niklaus; Jeker, Barbara; Müller, Rouven; Cairoli, Anne; Müller, Antonia M S; Bargetzi, Mario; Hitz, Felicitas; Baldomero, Helen; Heim, Dominik; Schmidt, Adrian; Rossi, Davide; Ghielmini, Michele; Wannesson, Luciano; Lerch, Erika; Samaras, Panagiotis; Schanz, Urs; Passweg, Jakob R; Stussi, Georg; Kleber, Martina; ... (2019). Melphalan dose in myeloma patients ≥65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study. Bone marrow transplantation, 54(7), pp. 1029-1037. Nature Publishing Group 10.1038/s41409-018-0379-y

Samaras, Panagiotis; Bargetzi, Mario; Betticher, Daniel C; Driessen, Christoph; Duchosal, Michel A; Heim, Dominik; Ketterer, Nicolas; Lerch, Erika; Matthes, Thomas; Mey, Ulrich; Pabst, Thomas; Schmidt, Adrian; Taverna, Christian; Zander, Thilo; Renner, Christoph (2019). Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss medical weekly, 2019(149), pp. 1-8. EMH Media 10.4414/smw.2019.20031

Voegeli, Michèle; Rondeau, Stephanie; Berardi Vilei, Simona; Lerch, Erika; Wannesson, Luciano; Pabst, Thomas; Rentschler, Jochen; Bargetzi, Mario; Jost, Lorenz; Ketterer, Nicolas; Bischof Delaloye, Angelika; Ghielmini, Michele (2017). Y(90) -Ibritumomab tiuxetan (Y(90) -IT) and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy: a feasibility trial (SAKK 37/05). Hematological oncology, 35(4), pp. 576-583. Wiley 10.1002/hon.2348

Samaras, Panagiotis; Bargetzi, Mario; Betticher, Daniel C; Duchosal, Michel A; Heim, Dominik; Hess, Urs; Ketterer, Nicolas; Lerch, Erika; Matthes, Thomas; Mey, Ulrich; Pabst, Thomas; Taverna, Christian; Zander, Thilo; Renner, Christoph (2015). Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. Swiss medical weekly, 145, w14100. EMH Schweizerischer Ärzteverlag 10.4414/smw.2015.14100

Wannesson, Luciano; Bargetzi, Mario; Cairoli, Anne; Cerutti, Alessandra; Heim, Dominik; Hess, Urs; Lerch, Erika; Pabst, Thomas; Renner, Christoph; Samaras, Panagiotis; Zucca, Emanuele (2013). Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone). Leukemia & lymphoma, 54(1), pp. 36-40. London: Informa Healthcare 10.3109/10428194.2012.702903

This list was generated on Thu Mar 28 10:20:37 2024 CET.
Provide Feedback